Showing 8 of 8 recruiting trials for “Precursor B-cell acute lymphoblastic leukemia”
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Enrolling by InvitationNCT03226704 ↗
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →